S. E. Harper

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis

Loren Laine, S. E. Harper, Thomas Simon et al. · Gastroenterology · 1999 · 476 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

Frank L. Lanza, M F Rack, Thomas Simon et al. · Alimentary Pharmacology & Therapeutics · 1999 · 170 citations

Medicine, Pharmacology, Pharmacotherapy +13

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

Richard H. Hunt, S. E. Harper, Douglas J. Watson et al. · The American Journal of Gastroenterology · 2003 · 163 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Complementary studies of the gastrointestinal safety of the cyclo‐oxygenase‐2‐selective inhibitor etoricoxib

Richard H. Hunt, S. E. Harper, P. Callegari et al. · Alimentary Pharmacology & Therapeutics · 2003 · 106 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

Christopher J. Hawkey, Loren Laine, S. E. Harper et al. · Alimentary Pharmacology & Therapeutics · 2001 · 56 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16